- Home
- BDSX
BDSX
Biodesix Inc.
as 09-05-2025 4:00pm EST
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | LOUISVILLE |
| Market Cap: | 53.2M | IPO Year: | 2020 |
| Target Price: | $1.75 | AVG Volume (30 days): | 4.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.17 - $1.90 | Next Earning Date: | 10-31-2025 |
| Revenue: | $76,556,000 | Revenue Growth: | 25.70% |
| Revenue Growth (this year): | 18.8% | Revenue Growth (next year): | 27.76% |
Stock Insider Trading Activity of Biodesix Inc. (BDSX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SCHULER JACK W | BDSX | Director, 10% Owner | Aug 29 '25 | Buy | $0.43 | 3,488,372 | $1,499,999.96 | 24,406,546 | |
| Vazquez Chris | BDSX | Chief Accounting Officer | Aug 13 '25 | Sell | $0.42 | 228 | $94.92 | 18,375 | |
| Pestano Gary Anthony | BDSX | Chief Development Officer | Aug 13 '25 | Sell | $0.42 | 442 | $184.00 | 157,878 | |
| Cowie Robin Harper | BDSX | CFO, Sec'y & Treasurer | Aug 13 '25 | Sell | $0.42 | 988 | $411.30 | 250,794 | |
| O'Kane Kieran | BDSX | Chief Commercial Officer | Aug 13 '25 | Sell | $0.42 | 476 | $198.16 | 140,065 | |
| Hutton Scott | BDSX | President & CEO | Aug 13 '25 | Sell | $0.42 | 3,772 | $1,570.28 | 728,824 |
Latest Biodesix Inc. News
BDSX Breaking Stock News: Dive into BDSX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
GlobeNewswire
3 months ago
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting
Simply Wall St.
4 months ago
Independent Director of Biodesix Picks Up 15% More Stock
GlobeNewswire
4 months ago
Biodesix to Participate in Upcoming Investor Conferences
MT Newswires
4 months ago
Biodesix Insider Bought Shares Worth $1,316,625, According to a Recent SEC Filing
Simply Wall St.
4 months ago
Biodesix, Inc. (NASDAQ:BDSX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Simply Wall St.
4 months ago
News Flash: 6 Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Earnings Are Under Threat
GlobeNewswire
4 months ago
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS
Compare BDSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDSX Biodesix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.